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Meningitis caused by Streptococcus pneumoniae has be-come the most common bacterial infection of the central
nervous system.31 It is rapidly fatal if not treated early and ef-
fectively with antibiotics that achieve bactericidal activity at the
site of infection, which is in the subarachnoid space filled
with cerebrospinal fluid (CSF).28 For the last 40-50 years, the
/3-lactam antibiotics have fulfilled this function. However, with
the emergence of resistance to these and other antibiotics, the
future approach to treatment of this infection could be prob-
lematic. This renewed interest in pneumococcal disease stimu-
lates us to review what we have learned about the pathophysi-
ology of this disease since the development of the Dacey/Sande
meningitis model in the early 1970s.5 It has always been our
hope that an in-depth understanding of the mediators that lead
to abnormalities in brain function and eventual neuronal death
would lead to therapeutic interventions that would reduce these
destructive consequences. Today, these goals are more impor-
tant than ever.
THE MODEL
The model was first described by Dacey and Sande in 1974,
when it was used to demonstrate that probenecid increased the
concentration of penicillin in the CSF fluid by blocking the or-
ganic acid exit pump located in the choroid plexus.5 The model
consisted of a rabbit suspended in a stereotactic frame that al-
lowed instillation of microorganisms (usually the pneumococ-
cus) directly into the cisterna magna of the animal and then,
with the needle left in place, continuous sampling of CSF as
the infection developed. CSF could be analyzed for viable bac-
teria, various mediators and indicators of inflammation, drug
concentrations as a function of simultaneous serum concentra-
tions, and CSF pressure. Brain histology and brain water con-
tent could be measured at the conclusion of the experiment.36
The unique ability to monitor the infection over time allowed
for a real-time assessment of the importance of the various com-
ponents of the inflammatory process and allowed a direct mea-
sure of their contribution to the pathophysiology of the disease
by the use of selective inhibitors. While the experimental work
has expanded into various other in vivo and in vitro models over
the past 30 years by numerous investigators, most of the initial
observations were made using this rabbit model.
THE INFECTION
It was found that a very low inoculum of encapsulated pneu-
mococci could produce a progressive infection in the rabbit,27
an observation confirmed by Moxon in the infant rat model of
Haemophilus influenza type b meningitis, who found that it only
took a single organism in the CSF to produce meningitis.21 Un-
encapsulated mutants were nonpathogenic. Each bacterial strain
had its own unique infectious dose 50 (ID50), which is the num-
ber of organisms necessary to produce progressive infection in
50% of the animals when directly injected into the CSF. This
proved to be a measure of virulence for the meningitis poten-
tial of the various bacteria. With a well-characterized type 3 S.
pneumoniae, the ID50 was less than 100 organisms. After in-
jection, a lag phase with stationary growth lasted for approxi-
mately 2 hr and then the bacteria grew with a generation (or
doubling) time of approximately 60 min (compared to 20 min
in broth) until they reached "maximum population densities" of
106-108 cfu/ml after 18-36 h. Adapting the model to the dog,
we found that shortly after initiation of log-phase growth in
CSF, the pneumococcus appeared in the sagittal sinus, followed
2 hr later by appearance in the arterial circulation, thus demon-
strating a unique clearance mechanism for bacteria from the
central nervous system.29
THE HOST'S RESPONSE
Within 8-12 hr after inoculation of the pneumococcus, white
blood cells (WBC) of the polymorphonuclear type appear in the
CSF. Just preceding this is an opening of the blood-brain bar-
rier extensively characterized by Scheid as an opening of the
tight junctions between brain capillary endothelial cells associ-
ated with enhanced pinocytotic activity.26 This results in the in-
flux of serum components, including chemotactic components
of the complement system, especially C5a, which is in part re-
sponsible for the polymorphonuclear leukocyte (PMN) migra-
tion.8 It is significant that the appearance of WBC has no ef-
fect on the rate of proliferation of the bacteria, and neutropenic
animals showed the same bacterial growth characteristics as
normal animals.7 This lack of effect of granulocytes in the CSF
against the encapsulated pathogen is a reflection of the low con-
centrations of opsonins (anti-capsular antibodies, complement)
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in this compartment of relative host defense deficiency.24,33
Consequently, when serum or anticapsular antibody was in-
jected directly into the CSF prior to inoculation of the S. pneu-
moniae, the WBCs effectively killed the bacteria (W.M. Scheid,
B. Perkins, and M.A. Sande, unpublished observations). Con-
versely, complement depletion of animals increases the viru-
lence of pneumococci during experimental meningitis.42 One
apparently effective host response in the CSF is the generation
of fever in the rabbit. Bacterial growth is significantly reduced
and the ID50 significantly increased in animals that were al-
lowed to developed high temperatures compared to those in
which the febrile response was suppressed.27'32
Another consistent pathophysiological alteration that devel-
oped during the first phase of infection in parallel with the open-
ing of the blood-brain barrier was the decline of CSF glucose
concentration (hypoglycorrhachia) and the increase in lactic
acid concentration.413 Both changes were felt to represent in-
creased utilization of glucose in response to relative cerebral is-
chemia caused by a reduction or mismatch of cerebral blood
flow and a subsequent switch to the glycolytic cycle and away
from the Krebs cycle of metabolism.10 This metabolic switch
utilizes more glucose and produces lactate. It has been shown
that tumor-necrosis factor-« (TNF-a), when injected directly
into the CSF, can induce this switch to anaerobic glycolysis
with a subsequent increase in CSF lactate concentrations.45
Other studies have implicated reduced glucose transport as an-
other potential cause of a low CSF glucose concentration.2
MOLECULAR MEDIATORS
OF INFLAMMATION IN MENINGITIS
One of the most fruitful areas of research in bacterial menin-
gitis was the exploration of the molecular mediators of inflam-
mation. The question, how the host recognizes the presence of
the pneumococcus in the subarachnoid space, and how it re-
sponds to this invasion could be addressed almost ideally in the
Dacey/Sande rabbit model, in which substances can be directly
injected into the CSF space and CSF can then be sampled al-
most continuously to monitor the response of the host. Work
by several groups, notably Alex Tomasz and Elaine Tuomanen
and their colleagues at Rockefeller University, has documented
that fragments of the bacterial cell, not the bacterial polysac-
charide capsule, are critical stimuli for the host's own inflam-
matory response.40-41 The pneumococcal cell wall is composed
of a sugar backbone consisting of alternating molecules of
A'-acetyl-muramic acid and /V-acetyl-glucosamine, which are
connected to a three-dimensional network by pentapeptide side
chains. In addition, the cell wall contains teichoic acid and
lipoteichoic acids. All of these components of the cell wall are
released as fragments from dying organisms undergoing autol-
ysis and are able to induce mononuclear macrophages to ex-
press and release proinflammatory cytokines, such as TNF-a,
interleukin-1 (IL-1 ), IL-6, and many others.43 Release of cell
wall fragments is dramatically increased immediately after ini-
tiation of antibiotic therapy, when large numbers of bacteria are
killed, and the increased liberation of cell wall fragments leads
to a heightened inflammatory response of the host.37-44 The ex-
act potency of various cell wall fragments of the pneumococ-
cus in inducing cytokines seems to vary, but small muramic
acid dipeptides are thought to represent the minimal proin-
flammatory unit. The composition and amount of cell wall frag-
ments released spontaneously or after initiation of antibiotic
therapy can vary substantially from one pneumococcal strain to
another. This variability may be one factor explaining the dra-
matic differences in the evolution of pathophysiologic changes,
when different pneumococcal strains are injected into the CSF
of rabbits.38
Induction of proinflammatory cytokines (TNF-a, IL-1,
IL-6) triggers a complex network of additional inflammatory
mediators that, in concert, regulate the humoral and cellular
inflammation during meningitis. Other proinflammatory
cytokines, anti-inflammatory cytokines such as IL-10 and trans-
forming growth factor-/3 (TGF-/3), soluble cytokine receptors,
and receptor antagonists, several members of the more recently
discovered class of chemokines, and lipid mediators such as
platelet activating factor (PAF) all appear to be involved in the
meningeal inflammation and the subsequent pathophysiologic
changes (for a recent review, see ref. 35). The complexity of
the inflammatory mediator network, and limitations of the cur-
rently used experimental systems rarely allow a conclusive de-
termination as to what extent bacterial components or host-
derived mediators are responsible for the changes observed dur-
ing bacterial meningitis. It is possible that the only role of bac-
terial products is to start and maintain the inflammatory re-
sponse of the host. Accordingly, inhibition of inflammatory
mediators by administration of corticosteroids or nonsteroidal
antiinflammatory drugs is effective in preventing the patho-
physiologic changes in models of meningitis, particularly when
the substances are given prior to the development of meningi-
tjs 36,44,47 Corticosteroids, with their broad mode of action,
which includes potent inhibition of cytokines, seem more ef-
fective in downmodulating inflammation and pathophysiologic
changes in meningitis than nonsteroidal antiinflammatory
drugs. The latter class of drugs, represented for example by in-
domethacin, primarily influences the generation of some lipid
mediators and has shown limited effects on the pathophysiol-
ogy of meningitis.47
ADVANCED PATHOPHYSIOLOGY
OF MENINGITIS
As a consequence of the increasing inflammatory reaction in
the subarachnoid and ventricular space, meningitis leads to mul-
tiple, well-defined alterations of the intracranial physiology.
These include brain edema, increased intracranial pressure, re-
duction in cerebral blood flow, and increased resistance to CSF
résorption.30-36-46-48 Increased intracranial pressure represents
probably the most critical single alteration that is both the re-
sult of other changes and contributes critically to cerebral is-
chemia with its devastating effect on the brain.48 Three factors
can contribute to increased intracranial pressure during menin-
gitis: brain edema, increased cerebral blood volume, and alter-
ations of CSF hydrodynamics, in particular disturbed CSF ré-
sorption.30-3 '-49 Brain edema in meningitis appears to be a
combination of vasogenic edema, resulting from the disruption
of the blood-brain barrier, cytotoxic edema, resulting from cy-
totoxic mediators such as excitatory amino acids (EAA, see be-
low), and interstitial edema.34 The latter is the consequence of
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a mechanical plugging of the CSF clearance system across the
arachnoid villi in the superior saggital sinus by the inflamma-
tion in the subarachnoid space.30 White blood cells, fibrin, and
bacteria collect in the villi, thus obstructing the CSF outflow
and leading to increased CSF pressure, increased intracranial
pressure, and possibly hydrocephalus. Downmodulation of in-
flammation with corticosteroids improves, as one would expect,
the function of the CSF clearance system across the arachnoid
villi.30 Finally, intracranial blood volume can also contribute to
increased intracranial pressure. Early in the disease, increased
blood flow to the brain (hyperemia) may be the most important
contributing factor to increased intracranial blood volume and
increased intracranial pressure.23 As the disease progresses,
blood flow is reduced overall, but the venous blood volume
may nevertheless be increased, leading to an increase of total
intracerebral blood volume.49
The most significant consequence of increased intracranial
pressure is its effect on cerebral blood flow. At least in severe
cases of meningitis, typically caused by pneumococci, cerebral
blood flow autoregulation is impaired and cerebral blood flow
is directly dependent on cerebral perfusion pressure, which re-
sults from arterial pressure minus intracranial pressure.46-48
Thus, high intracranial pressure directly reduces cerebral per-
fusion pressure (particularly when the patient at the same time
has a low systemic blood pressure because of dehydration or
sepsis) and thus leads to reduced cerebral blood flow and sub-
sequent cerebral ischemia.48-39 In practical terms, correction of
cerebral perfusion pressure by normalizing arterial blood pres-
sure and reducing intracranial hypertension is one of the most
critical goals of the supportive management of patients with se-
vere meningitis.
MECHANISMS OF BRAIN DAMAGE
The net result of the many changes occurring in the brain
during meningitis is the development of brain damage, charac-
terized by neuronal dropout and other, less well-defined cellu-
lar changes in the brain. As a clinical result, patients who sur-
vive the disease with neuronal damage show neurologic
sequelae, such as learning deficits, mental retardation, sensory-
motor deficits, and seizure disorders.9 The most common neu-
rologic sequelae is hearing loss, which appears to result from
inflammation affecting the inner ear after direct extension from
the subarachnoid space along the cochlear aqueduct into the
perilymphatic space of the cochlea.1-6 Molecular mediators of
the processes that lead to the destruction of the hair cells of the
inner ear are incompletely characterized, but may involve cy-
tokines, oxygen-derived radicals, and, in the case of the pneu-
mococcus, the bacteria-derived, highly potent cytotoxin pneu-
molysin.3
The molecular mechanisms that lead to neuronal damage dur-
ing meningitis have started more recently to emerge from work
in infant rats with experimental meningitis. Initial studies in this
model were performed using group B streptococci as the in-
fecting organism, but more recent experiments have shown that
the pneumococcus produces very similar alterations as the
group B streptococcus. The advantage of this model is the fact
that substantial neuronal injury occurs as a result of the dis-
ease.15 This is in contrast to most other models of meningitis
previously employed, particularly the rabbit model, where very
little neuropathologic changes can be identified even in ad-
vanced meningitis. The new model has thus opened the door to
investigate directly the role of various mediators in causing neu-
ronal injury. The most important form of neuronal injury in this
model involves focal cortical injury that resembles very much
the focal damage seen in neonates and young children suffer-
ing from meningitis.15 The morphology of these changes shows
all of the features of ischémie cortical damage, i.e., it is wedge-
shaped and most severe in watershed areas of the cerebral cir-
culation. Indeed, bloodflow studies have documented severe fo-
cal ischemia in the model in a pattern that was identical to the
histopathologic changes observed. Further supporting the is-
chémie nature of the cortical injury were studies that showed
improved neurologic outcome in animals, in which the extent
of blood flow changes was reduced, and worsened neurologic
outcome, when blood flow changes were aggravated. Thus,
molecular mediators of blood flow alterations during meningi-
tis became an important area of investigation in this model.
Early in experimental meningitis, cerebral blood flow in-
creases as a result of vasodilation. Work in an adult rat model
of pneumococcal meningitis by Walter Pfister's group in Mu-
nich has documented that this early vasodilation is mediated by
nitric oxide (NO).16 We have found subsequently that NO con-
tinues to play an important role as regulator of cerebral blood
flow far into the course of the disease.19 We observed that in-
hibition of the inducible nitric oxide synthase (NOS), which is
upregulated during meningitis in the subarachnoid space in-
flammation and vasculature, and which is responsible at least
for part of the NO produced during meningitis, led to a harm-
ful increase in cerebral ischemia in animals with advanced
meningitis. This increased ischemia was associated with an in-
crease in neuronal damage. Thus, NO produced by the inducible
NOS in or close to the cerebral vasculature has a beneficial ef-
fect, because its vasodilative effect counteracts other processes
that tend to lead to vasoconstriction and subsequent ischemia.
Some of the vasoconstrictive mediators have also been iden-
tified. Most notable are oxygen-derived radicals, such as Su-
peroxide, hydrogen peroxide, and others. These metabolic prod-
ucts of essential biologic processes, such as mitochondrial
respiratory chain and activation of macrophages, have multiple
harmful effects on cells and macromolecules, including lipid
peroxidation, DNA damage, and protein oxidation. In the in-
fant rat model of meningitis, lipid peroxidation is strongly in-
creased in advanced disease, and histochemical methods have
allowed direct localization of the production of Superoxide to
the subarachnoid space and the cerebral vasculature.17 Impor-
tantly, scavenging of these radicals by so-called spin-trapping
agents, which can bind and detoxify radicals, led to a reduction
of lipid peroxidation, but also to an improvement of cerebral
blood flow with associated reduction of ischémie neuronal dam-
age.17 Thus, oxidative radicals (by mechanisms that are cur-
rently not completely understood) are important mediators of
vasoconstriction during meningitis, and their inhibition is ben-
eficial by improving cerebral blood flow. Another molecule
with vasoconstrictive properties that has recently been impli-
cated in the ischemia developing during meningitis is endothe-
lin. This vasoactive peptide is increased in the CSF of patients
with meningitis, and we found that an endothelin-receptor an-
tagonist, bosentan, dramatically improved the neurologic out-
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come of meningitis in the infant rat model, apparently at least
in part by improving cerebral blood flow (Pfister et al., in press).
Other mediators of vasoconstriction likely play also a role
in meningitis and will need to be identified in future studies.
It is likely that increased local coagulation leads to thrombosis
with associated disturbances of cerebral blood flow, but this has
not been investigated in any of the available models of menin-
gitis.
Some of the molecules that are directly neurotoxic during
meningitis have also been identified. Because ischemia appears
to play a critical role in causing brain injury, studies have fo-
cused on the role of excitatory amino acids (EAA) in causing
neuronal cell death. EAA (e.g., glutamate) are physiologic neu-
rotransmitters that are released at increased concentrations from
neurons subjected to stress, such as ischemia or hypoglycemia.
Their increased concentrations in the extracellular fluid leads
to overstimulation of postsynaptic EAA receptors, in particular
the NMDA receptor, with subsequent increased influx of cal-
cium through the receptor channel, activation of various cellu-
lar pathways, including production of NO by neuronal NOS,
and generation of oxidative radicals. All of these processes ul-
timately lead to cellular death. This appears to be an important
mechanism of cell death in stroke. In models of meningitis, we
and others have documented an increase in glutamate concen-
trations both in the CSF and, more importantly, in the inter-
cellular fluid, and have shown that an antagonist of the NMDA
receptor, kynurenic acids, is neuroprotective.1 '-18-22 Thus, EAA
represent the first neurotoxic molecule shown directly to play
a role in bacterial meningitis.
One consequence of overstimulation of NMDA receptors is
the generation of NO by neurons containing neuronal NOS. NO
can potentially be neurotoxic directly, as shown in brain cell
culture systems stimulated with pneumococcal cell walls,14 or
it can combine with Superoxide to form the highly cytotoxic
molecule peroxynitrite (ONOO). Superoxide is likely to be
formed during meningitis in the brain, either as a result of is-
chémie insult and the associated activation of the glycolytic
pathway, or as a result of activation of microglia and other
phagocytic cells by cytokines and bacterial products. Prelimi-
nary evidence suggests that peroxynitrite is indeed formed in
the brain during experimental meningitis, and that it contributes
to the development of neuronal injury. In the infant rat model,
we found evidence for increased production of nitrotyrosine,
the chemical hallmark of the presence of peroxynitrite, by im-
munocytochemistry and high-performance liquid chromatogra-
phy (HPLC) (unpublished observations). A role of peroxyni-
trite in meningitis was further supported by treatment studies.
Both a scavenger of peroxynitrite (uric acid), and an inhibitor(3-aminobenzamine) of the enzyme poly-(ADP-ribose) poly-
merase (PARP), which is activated by the action of peroxyni-
trite on mitochondria, significantly reduced neuronal injury in
the treated compared to the untreated animals.12
Thus, molecules that contribute to the demise of neurons dur-
ing meningitis may emerge as targets for adjunctive therapy. It
would appear that a combined inhibition of oxidative radicals,
EAA, and peroxynitrite should have profound effects on the de-
velopment of neuronal injury. Such therapies could be effec-
tive even when instituted in relatively advanced stages of the
disease, since the interrupted pathways are late events in the se-
quence leading from subarachnoid space inflammation to neu-
ronal injury. Specific neuroprotective therapies could represent
a potential advantage over the use of corticosteroids, which act
primarily by downmodulating inflammation and thus at a rela-
tively early stage in the pathophysiologic cascade of meningi-
tis. This effect primarily on early events in meningitis may, at
least in part, be a reason why corticosteroids, although clearly
beneficial in several clinical studies, have shown overall mod-
est benefits. This has led to a continued controversy regarding
their usefulness in meningitis.20-25 We hope that the lessons that
have been and will be learned from the use of models such as
the Dacey/Sande rabbit model will lead to new therapies that
can improve the outcome of bacterial meningitis.
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